Newly developed drug shows promise against a novel oncogene that supports cancer progression

In findings recently published in the Journal of Medicinal Chemistry, Daniel LaBarbera, PhD and colleagues describe the optimization of the first lead CHD1L inhibitors (CHD1Li) through drug design and medicinal chemistry.